Enliven Therapeutics Valuation
| ELVN Stock | 25.41 1.06 4.35% |
At this time, the firm appears to be fairly valued. Enliven Therapeutics shows a prevailing Real Value of USD26.18 per share. The current price of the firm is USD25.41. Our model computes the value of Enliven Therapeutics from reviewing the firm fundamentals such as Current Valuation of 897.97 M, shares owned by insiders of 6.39 %, and Number Of Shares Shorted of 6.91 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Enliven Therapeutics' valuation include:
Price Book 4.1252 | Enterprise Value 898 M | Enterprise Value Ebitda (6.28) |
Fairly Valued
Today
Please note that Enliven Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Enliven Therapeutics is based on 3 months time horizon. Increasing Enliven Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Enliven Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enliven Stock. However, Enliven Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.41 | Real 26.18 | Target 31.0 | Hype 25.31 | Naive 25.06 |
The intrinsic value of Enliven Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Enliven Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Enliven Therapeutics helps investors to forecast how Enliven stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enliven Therapeutics more accurately as focusing exclusively on Enliven Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Enliven Therapeutics' intrinsic value based on its ongoing forecasts of Enliven Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Enliven Therapeutics' closest peers.
Enliven Therapeutics Cash |
|
Enliven Valuation Trend
Knowing Enliven Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Enliven Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Enliven Therapeutics Total Value Analysis
Enliven Therapeutics is currently anticipated to have valuation of 897.97 M with market capitalization of 1.19 B, debt of 335 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Enliven Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
897.97 M | 1.19 B | 335 K |
Enliven Therapeutics Asset Utilization
One of the ways to look at asset utilization of Enliven is to check how much profit was generated for every dollar of assets it reports. Enliven Therapeutics shows a negative utilization of assets of -0.21 percent, losing USD0.002137 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Enliven Therapeutics shows how discouraging it operates for each dollar spent on its assets.Enliven Therapeutics Ownership Allocation
Enliven Therapeutics holds a total of 48.86 Million outstanding shares. The majority of Enliven Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enliven Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enliven Therapeutics. Please pay attention to any change in the institutional holdings of Enliven Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost two million five hundred six thousand four hundred seventy-seven invesors are currently shorting Enliven Therapeutics expressing very little confidence in its future performance.Enliven Therapeutics Profitability Analysis
Net Loss for the year was (71.58 M) with profit before overhead, payroll, taxes, and interest of 0.About Enliven Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Enliven Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Enliven Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Enliven Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Enliven Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Enliven Therapeutics. We calculate exposure to Enliven Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enliven Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -297 K | -311.9 K |
Enliven Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 35.5 M |
Enliven Therapeutics Current Valuation Indicators
Enliven Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Enliven Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Enliven Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Enliven Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Enliven Therapeutics' worth.When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.